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Preoperative platelet inhibition and
bleeding after cardiopulmonary
bypass
To the Editor:
Bizzari and associates1 studied clinical
events and potential bleeding complica-
tions in a group of patients who had under-
gone emergency or urgent cardiac surgery
after treatment with tirofiban hydrochlo-
ride. They observed that patients treated
with tirobifan had a smaller decrease in
platelet count during cardiopulmonary by-
pass; other platelet suppressants have sim-
ilar effects.2,3 Preoperative platelet inhibi-
tion will reduce the platelet loss associated
with cardiopulmonary bypass because a
preferential loss of activated platelets is
observed during the period of extracorpo-
real circulation.4,5 The hemostatic function
of the preserved platelets would, however,
be impaired by heparin-induced plasma
changes.6
The study was undertaken because of a
concern that platelet inhibition may exac-
erbate bleeding after cardiopulmonary by-
pass. We among others have demonstrated
that during cardiopulmonary bypass plate-
lets lose the ability to form large stable
aggregates (macroaggregates).6-9 This im-
pairment persists for several hours postop-
eratively.7,8 Macroaggregation is important
for platelet hemostatic function because it
gives strength to a platelet plug and paves
the way for clot retraction. As platelet mac-
roaggregation is virtually abolished during
cardiopulmonary bypass,6-9 we suggest that
additional platelet suppression is unlikely
further to impair hemostasis or increase
bleeding during the immediate postopera-
tive period. Furthermore, after cardiopul-
monary bypass platelets appear resistant to
aspirin,10 an irreversible platelet inhibi-
tor; it is therefore unlikely that even
long-acting platelet suppressants that are
administered preoperatively will signifi-
cantly impair platelets late in the postop-
erative period. This would explain why
patients who received platelet suppres-
sants shortly before undergoing surgery
using cardiopulmonary bypass did not
appear to bleed excessively when com-
pared with those who did not receive
these drugs.1-3
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Transapical aortic cannulation for
acute aortic dissection with diffuse
atherosclerosis
To the Editor:
We read with interest the article by Fukuda
and associates1 and congratulate them on
their good results. We agree that femoral
artery cannulation sometimes must be
abandoned as arterial access for cardiopul-
monary bypass. Recently we operated on
an urgent basis on a 54-year-old man with
type A acute aortic dissection. The femoral
artery could not be used as arterial access
because of tinea inguinalis. We chose the
subclavian artery instead.
We doubt the reliability of transapical
aortic cannulation in median sternotomy.
We suspect that Fukuda and associates1
happened to dodge the drawbacks of using
this procedure by mere luck, because hy-
potension during elevation of the apex, dis-
location of the cannula, incompetence of
the aortic valve, and repair of the insertion
site are usually inevitable. Insufficient
myocardial protection because of the in-
ability to clamp the ascending aorta and to
administer cardioplegic solution remains a
problem to be solved. If Fukuda and asso-
ciates1 have had experience with other
Letters to the Editor
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 3 739
